Ask me later
Ask me later
How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Thanks again for rating us!
Calliditas: Feedback from Novartis Iptacopan challenger
Novartis has a Nephrology pipeline base on Iptacopan, and one target therapy is lgAN. As a result, Iptacopan is one future potential Nefecon challenger. During the ongoing ERA-ERDTA Congress, Novartis presented top-line phase II results based on 112 patients after 90 days.
JU
Johan Unnerus
Disclosures and disclaimers